Valeant Pharmaceuticals Intl (VRX) 30.12 $VRX
Pharma Round-Up: Mylan's Antitrust Probe, Allergan Limits Drug Price Hikes
Madeleine Johnson - Zacks Investment Research - Tue Sep 06, 4:13PM CDT
On Tuesday, New York Attorney General Eric Schneiderman opened an investigation into Mylan NV (MYL), while Allergan Inc.'s (AGN) CEO Brett Saunders has offered a promise to limit price hikes on the drugs it sells.
AGN: 239.12 (+3.16), VRX: 30.12 (+0.65), MYL: 40.87 (+0.47)
Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets
CNW Group - Tue Sep 06, 4:00PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant"
and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) ("Progenics" today announced the U.S. commercial launch of RELISTOR(®) (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.
PGNX: 6.45 (+0.29), VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
Drug Stocks Remain in Focus as Pricing Debate Continues
Arpita Dutt - Zacks Investment Research - Mon Sep 05, 7:38AM CDT
Mylan (MYL) finds itself in troubled waters with lawmakers now questioning Medicaid rebates for EpiPen.
MDVN: 80.84 (-0.01), VRX: 30.12 (+0.65), VRTX: 95.78 (+0.67), GILD: 78.00 (+0.12), MYL: 40.87 (+0.47)
Valeant Pharmaceuticals trade offers a 16% return in 198 days, or find similar option trades on Weight Watchers, EMC Corporation, Twilio Inc., and Square Incorporated
PR Newswire - Wed Aug 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EMC, SQ, TWLO, VRX, and WTW.
VRX: 30.12 (+0.65), TWLO: 59.85 (+0.67), EMC: 29.05 (+0.28), WTW: 10.28 (+0.02), SQ: 11.79 (-0.04)
Orexigen Stock Up on Commercialization Deal for Contrave
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:11AM CDT
Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.
OREX: 3.74 (-0.12), VRX: 30.12 (+0.65), ANIP: 61.55 (+1.69), PCRX: 40.79 (+1.75)
Valeant Pharmaceuticals To Participate In September Healthcare Conferences
CNW Group - Tue Aug 30, 4:00PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company" today announced that Joseph C. Papa, Chairman and CEO, will participate in the following healthcare conferences in September:
VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
Watch for Valeant Pharmaceuticals International to Potentially Rebound After Falling 1.22% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 11:57AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $30.00 to a high of $31.20. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $30.27 on volume of 10.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRX: 30.12 (+0.65)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 31.52 (-0.27), ENDP: 20.49 (+0.67), VRX: 30.12 (+0.65), BSTC: 36.10 (-0.46), MYL: 40.87 (+0.47), TEVA: 51.08 (-0.25), USNA: 138.69 (+0.53)
Mylan boosts EpiPen patient programs, doesn't budge on price
By LINDA A. JOHNSON and TOM MURPHY - AP - Thu Aug 25, 4:45PM CDT
The maker of EpiPens offered patients more help to pay for its costly emergency allergy shots but didn't budge Thursday on the $608 price.
ESRX: 72.72 (+0.18), VRX: 30.12 (+0.65), MYL: 40.87 (+0.47), VRX.TO: 37.86 (+0.52)
After Yesterday's Rally of 3.14% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Aug 24, 11:44AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $31.25 to a high of $32.74. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $31.99 on volume of 22.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 30.12 (+0.65)
Stock Market News for August 23, 2016
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:10AM CDT
Benchmarks closed mostly in the red on Monday after a decline in crude prices weighed on energy sector and eventually on the Dow and S&P 500
CST: 48.10 (+0.25), TSLA: 204.50 (+1.67), VRX: 30.12 (+0.65), PFE: 34.76 (-0.01), HAL: 43.73 (+0.41), SLB: 78.78 (+0.23), DLPH: 70.47 (+0.30), MS: 31.75 (-0.14), MDVN: 80.84 (-0.01), PXD: 184.99 (+1.49), MRO: 15.64 (unch), CVX: 102.43 (+1.50), MBLY: 49.00 (+0.07)
Valeant Pharmaceuticals trade offers a 17% return in 206 days, or find similar option trades on The Blackstone Group, Best Buy Inc., Northrup Grumman Corporation, and Suncor Energy
PR Newswire - Tue Aug 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BBY, BX, NOC, SU, and VRX.
SU: 27.52 (+0.09), VRX: 30.12 (+0.65), BX: 26.69 (-0.01), NOC: 214.76 (+1.52), BBY: 38.24 (-0.51)
Blog Coverage Valeant Pharma Appoints New CEO
ACCESSWIRE - Tue Aug 23, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 23, 2016 / Active Wall St. blog coverage looks at the headlines from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Zoetis Inc. (NYSE: ZTS). Zoetis announced on August 21, 2016, that it had appointed Glenn David as its Executive Vice President and Chief Financial Officer (CFO). The announcement came in the wake of the resignation of Executive Vice President and CFO Paul S. Herendeen on August 18, 2016. On August, 22, 2016, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced the appointment of Paul S. Herendeen to take on the role of CFO from Robert L. Rosiello. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
AGN: 239.12 (+3.16), ZTS: 51.24 (-0.05), VRX: 30.12 (+0.65), TROW: 69.08 (-0.19), VRX.TO: 37.86 (+0.52)
Pharming Convene an Extraordinary General Meeting of Shareholders
PR Newswire Europe - Tue Aug 23, 12:02AM CDT
LEIDEN, The Netherlands, August 23, 2016 /PRNewswire/ --
VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
Valeant Pharmaceuticals (VRX) Appoints New CFO, Stock Gains 7.2%
Afrasiab Mian - Zacks Investment Research - Mon Aug 22, 12:16PM CDT
Shares of Valeant Pharmaceuticals (VRX) were up over 7% in midday trading on Monday after the company announced the appointment of a new Chief Financial Officer (CFO).
VRX: 30.12 (+0.65)
Valeant, attempting to normalize operations, names new CFO
AP - Mon Aug 22, 11:21AM CDT
NEW YORK (AP) — Valeant Pharmaceuticals replaced Robert Rosiello as chief financial officer as the embattled company attempts to normalize operations amid a host of investigations and class action lawsuits.
VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer
CNW Group - Mon Aug 22, 5:00AM CDT
Robert L. Rosiello to Remain at Valeant as Executive Vice President, Corporate Development and Strategy
VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
Pharma Round-Up: Mylan's Antitrust Probe, Allergan Limits Drug Price Hikes
Madeleine Johnson - Zacks Investment Research - Tue Sep 06, 4:13PM CDT
On Tuesday, New York Attorney General Eric Schneiderman opened an investigation into Mylan NV (MYL), while Allergan Inc.'s (AGN) CEO Brett Saunders has offered a promise to limit price hikes on the drugs it sells.
AGN: 239.12 (+3.16), VRX: 30.12 (+0.65), MYL: 40.87 (+0.47)
Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets
CNW Group - Tue Sep 06, 4:00PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant"
and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) ("Progenics" today announced the U.S. commercial launch of RELISTOR(®) (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016. PGNX: 6.45 (+0.29), VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
Drug Stocks Remain in Focus as Pricing Debate Continues
Arpita Dutt - Zacks Investment Research - Mon Sep 05, 7:38AM CDT
Mylan (MYL) finds itself in troubled waters with lawmakers now questioning Medicaid rebates for EpiPen.
MDVN: 80.84 (-0.01), VRX: 30.12 (+0.65), VRTX: 95.78 (+0.67), GILD: 78.00 (+0.12), MYL: 40.87 (+0.47)
Valeant Pharmaceuticals trade offers a 16% return in 198 days, or find similar option trades on Weight Watchers, EMC Corporation, Twilio Inc., and Square Incorporated
PR Newswire - Wed Aug 31, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EMC, SQ, TWLO, VRX, and WTW.
VRX: 30.12 (+0.65), TWLO: 59.85 (+0.67), EMC: 29.05 (+0.28), WTW: 10.28 (+0.02), SQ: 11.79 (-0.04)
Orexigen Stock Up on Commercialization Deal for Contrave
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:11AM CDT
Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.
OREX: 3.74 (-0.12), VRX: 30.12 (+0.65), ANIP: 61.55 (+1.69), PCRX: 40.79 (+1.75)
Valeant Pharmaceuticals To Participate In September Healthcare Conferences
CNW Group - Tue Aug 30, 4:00PM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company"
today announced that Joseph C. Papa, Chairman and CEO, will participate in the following healthcare conferences in September: VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
Watch for Valeant Pharmaceuticals International to Potentially Rebound After Falling 1.22% Yesterday
Comtex SmarTrend(R) - Mon Aug 29, 11:57AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $30.00 to a high of $31.20. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $30.27 on volume of 10.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRX: 30.12 (+0.65)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 31.52 (-0.27), ENDP: 20.49 (+0.67), VRX: 30.12 (+0.65), BSTC: 36.10 (-0.46), MYL: 40.87 (+0.47), TEVA: 51.08 (-0.25), USNA: 138.69 (+0.53)
Mylan boosts EpiPen patient programs, doesn't budge on price
By LINDA A. JOHNSON and TOM MURPHY - AP - Thu Aug 25, 4:45PM CDT
The maker of EpiPens offered patients more help to pay for its costly emergency allergy shots but didn't budge Thursday on the $608 price.
ESRX: 72.72 (+0.18), VRX: 30.12 (+0.65), MYL: 40.87 (+0.47), VRX.TO: 37.86 (+0.52)
After Yesterday's Rally of 3.14% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Aug 24, 11:44AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $31.25 to a high of $32.74. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $31.99 on volume of 22.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 30.12 (+0.65)
Stock Market News for August 23, 2016
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 9:10AM CDT
Benchmarks closed mostly in the red on Monday after a decline in crude prices weighed on energy sector and eventually on the Dow and S&P 500
CST: 48.10 (+0.25), TSLA: 204.50 (+1.67), VRX: 30.12 (+0.65), PFE: 34.76 (-0.01), HAL: 43.73 (+0.41), SLB: 78.78 (+0.23), DLPH: 70.47 (+0.30), MS: 31.75 (-0.14), MDVN: 80.84 (-0.01), PXD: 184.99 (+1.49), MRO: 15.64 (unch), CVX: 102.43 (+1.50), MBLY: 49.00 (+0.07)
Valeant Pharmaceuticals trade offers a 17% return in 206 days, or find similar option trades on The Blackstone Group, Best Buy Inc., Northrup Grumman Corporation, and Suncor Energy
PR Newswire - Tue Aug 23, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BBY, BX, NOC, SU, and VRX.
SU: 27.52 (+0.09), VRX: 30.12 (+0.65), BX: 26.69 (-0.01), NOC: 214.76 (+1.52), BBY: 38.24 (-0.51)
Blog Coverage Valeant Pharma Appoints New CEO
ACCESSWIRE - Tue Aug 23, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 23, 2016 / Active Wall St. blog coverage looks at the headlines from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Zoetis Inc. (NYSE: ZTS). Zoetis announced on August 21, 2016, that it had appointed Glenn David as its Executive Vice President and Chief Financial Officer (CFO). The announcement came in the wake of the resignation of Executive Vice President and CFO Paul S. Herendeen on August 18, 2016. On August, 22, 2016, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced the appointment of Paul S. Herendeen to take on the role of CFO from Robert L. Rosiello. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
AGN: 239.12 (+3.16), ZTS: 51.24 (-0.05), VRX: 30.12 (+0.65), TROW: 69.08 (-0.19), VRX.TO: 37.86 (+0.52)
Pharming Convene an Extraordinary General Meeting of Shareholders
PR Newswire Europe - Tue Aug 23, 12:02AM CDT
LEIDEN, The Netherlands, August 23, 2016 /PRNewswire/ --
VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
Valeant Pharmaceuticals (VRX) Appoints New CFO, Stock Gains 7.2%
Afrasiab Mian - Zacks Investment Research - Mon Aug 22, 12:16PM CDT
Shares of Valeant Pharmaceuticals (VRX) were up over 7% in midday trading on Monday after the company announced the appointment of a new Chief Financial Officer (CFO).
VRX: 30.12 (+0.65)
Valeant, attempting to normalize operations, names new CFO
AP - Mon Aug 22, 11:21AM CDT
NEW YORK (AP) — Valeant Pharmaceuticals replaced Robert Rosiello as chief financial officer as the embattled company attempts to normalize operations amid a host of investigations and class action lawsuits.
VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer
CNW Group - Mon Aug 22, 5:00AM CDT
Robert L. Rosiello to Remain at Valeant as Executive Vice President, Corporate Development and Strategy
VRX: 30.12 (+0.65), VRX.TO: 37.86 (+0.52)
